R White, MD
Pulmonary Disease · Rochester, NYNPI 1366477044
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Merck accounts for 86.7% of it on its own, with 5 other manufacturers making up the rest. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $733.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$210K
- United Therapeutics Corporation$21K
- Bayer$11K
- Sandoz$247
- Actelion Pharmaceuticals US, Inc.$191
- Gilead$86
Across 90 payments — averaging $31,274 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.2M
- United Therapeutics Corporation$406K
- Janssen Research & Development, LLC$131K
- Bayer$31K
What the payments were for
- Consulting fees$77,66532%
- Speaking & faculty fees$29,96912%
- Travel & lodging$124,31051%
- Food & beverage$9,5324%
- Education$6690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 182 | $209,859 |
| United Therapeutics Corporation | 132 | $21,119 |
| Bayer | 8 | $10,644 |
| Sandoz | 5 | $247 |
| Actelion Pharmaceuticals US, Inc. | 2 | $191 |
| Gilead | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$242,145 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 224 | $4,826,542 |
| Ambrisentan | 838 | $3,300,818 |
| Tyvaso DpiTreprostinil | 154 | $3,297,164 |
| AdempasRiociguat | 161 | $2,149,904 |
| Tadalafil | 1,115 | $1,556,618 |
| WinrevairSotatercept-Csrk | 80 | $1,122,870 |
| LetairisAmbrisentan | 28 | $356,657 |
| AdcircaTadalafil | 39 | $163,231 |
| OpsumitMacitentan | 11 | $138,710 |
| JardianceEmpagliflozin | 127 | $138,387 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $28,340 |
| EliquisApixaban | 28 | $24,005 |
| XareltoRivaroxaban | 18 | $18,582 |
| Torsemide | 161 | $4,933 |
| Spironolactone | 203 | $3,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $10,644 | $2,149,904161 claims |
| MerckWinrevair | $209,859 | $1,122,87080 claims |
| GileadLetairis | $86 | $356,65728 claims |
| United Therapeutics CorporationAdcirca | $21,119 | $163,23139 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $191 | $138,71011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Rochester
- Michael LarjRochester$229K
- Daniel LachantRochester$141K
- Jason LyonsRochester$55K
- Christina BachRochester$53K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.